Prior data provide clinical proof-of-concept for narazaciclib’s mechanism of action in endometrial cancer Preliminary data from trial’s Phase 1 portion…
FDA removes partial clinical hold on seclidemstat Phase 1/2 trial in Ewing sarcoma; Salarius plans to meet with FDA to…
agenT-797, an allo-iNKT cell therapy, shows clinical responses in heavily pre-treated solid tumor cancers when administered with anti-PD-1 and persists…
NEEDHAM, Mass., May 11, 2023 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage…
Completed enrollment of the pivotal STRIDE study; topline results anticipated 4Q 2023Raised $68.3 million in gross proceeds from a concurrent…
MILAN, Italy, May 11, 2023 (GLOBE NEWSWIRE) -- The Italy Healthcare Innovation Summit, an event organized by Bamberg Health, attracted…
DUBLIN, Ireland, May 11, 2023 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming…
MOUNTAIN VIEW, Calif., May 10, 2023 (GLOBE NEWSWIRE) -- G-Tech Medical today announced an oral presentation of an abstract entitled…
Celularity has been advised by the Tamer Group to expect at least $60 million to $80 million in 2023 purchase…